Overview

Study Comparing SPP100 (Aliskiren) 150mg to Placebo and to Losartan 50mg in Patients With Mild to Moderate Essential Hypertension

Status:
Completed
Trial end date:
2007-04-01
Target enrollment:
Participant gender:
Summary
Assessing efficacy, safety and pharmacokinetics in patients with mild to moderate essential hypertension
Phase:
Phase 3
Details
Lead Sponsor:
Novartis
Treatments:
Losartan